GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Research & Development

HBPCF (Helix BioPharma) Research & Development : $4.72 Mil (TTM As of Jan. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Helix BioPharma's Research & Development for the three months ended in Jan. 2025 was $0.59 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2025 was $4.72 Mil.

Helix BioPharma Research & Development Historical Data

The historical data trend for Helix BioPharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Research & Development Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.35 4.69 3.51 4.00 4.36

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 1.09 2.09 0.96 0.59

Helix BioPharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma  (OTCPK:HBPCF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Helix BioPharma Research & Development Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Research & Development
Comparable Companies
TSXV:SHRX TSXV:NRX XCNQ:GLAB TSX:SVA XCNQ:DTC TSX:MBX TSXV:TTI TSXV:GSD NEOE:BMND TSXV:COV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
HBP0:Germany HBP:Canada
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Website
https://www.helixbiopharma.com
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.